Cather JC - Search Results

1

A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.

Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A. Leonardi CL, et al. Among authors: cather jc. Dermatology. 2006;213(3):204-14. doi: 10.1159/000095037. Dermatology. 2006. PMID: 17033169

2

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis.

Menter A, Cather JC, Baker D, Farber HF, Lebwohl M, Darif M. Menter A, et al. Among authors: cather jc. J Am Acad Dermatol. 2006 Jan;54(1):61-3. doi: 10.1016/j.jaad.2005.10.006. J Am Acad Dermatol. 2006. PMID: 16384756

3

Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab.

Cather JC, Cather JC, Menter A. Cather JC, et al. Expert Opin Biol Ther. 2003 Apr;3(2):361-70. doi: 10.1517/14712598.3.2.361. Expert Opin Biol Ther. 2003. PMID: 12662148 Review.

4

Efalizumab: continuous therapy for chronic psoriasis.

Cather JC, Menter A. Cather JC, et al. Expert Opin Biol Ther. 2005 Mar;5(3):393-403. doi: 10.1517/14712598.5.3.393. Expert Opin Biol Ther. 2005. PMID: 15833076 Review.

5

Combining traditional agents and biologics for the treatment of psoriasis.

Cather JC, Menter A. Cather JC, et al. Semin Cutan Med Surg. 2005 Mar;24(1):37-45. doi: 10.1016/j.sder.2005.01.002. Semin Cutan Med Surg. 2005. PMID: 15900797 Review.

6

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.

Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kricorian G, Nirula A. Papp KA, et al. Br J Dermatol. 2016 Aug;175(2):273-86. doi: 10.1111/bjd.14493. Epub 2016 Jun 23. Br J Dermatol. 2016. PMID: 26914406 Clinical Trial.

7

Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies.

Menter A, Cather JC, Jarratt M, Meng X, Guana A, Nyirady J. Menter A, et al. Among authors: cather jc. Dermatol Ther (Heidelb). 2016 Dec;6(4):639-647. doi: 10.1007/s13555-016-0140-7. Epub 2016 Aug 30. Dermatol Ther (Heidelb). 2016. PMID: 27576559 Free PMC article.

8

Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Papp K, Cather JC, Rosoph L, Sofen H, Langley RG, Matheson RT, Hu C, Day RM. Papp K, et al. Among authors: cather jc. Lancet. 2012 Aug 25;380(9843):738-46. doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29. Lancet. 2012. PMID: 22748702 Clinical Trial.

9

Update on botulinum toxin for facial aesthetics.

Cather JC, Cather JC, Menter A. Cather JC, et al. Dermatol Clin. 2002 Oct;20(4):749-61. doi: 10.1016/s0733-8635(02)00043-8. Dermatol Clin. 2002. PMID: 12380062 Review.

10

Oral erosions and cutaneous bullae.

Gleaves TR, Cather JC, Menter A. Gleaves TR, et al. Among authors: cather jc. Proc (Bayl Univ Med Cent). 2005 Jan;18(1):71-3. doi: 10.1080/08998280.2005.11928035. Proc (Bayl Univ Med Cent). 2005. PMID: 16200149 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

73 results

Search Page

Filters